POLB.LSE Poolbeg Pharma PLC

Healthcare Biotechnology London Exchange
0.0639 GBX
Close of Nov 3, 2026
3.30 9.30
Market cap
GBX 48.8M
P/E
-
P/B
7.40x
ROE
-115.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is POLB.LSE undervalued?

Graham number

The Graham number of Poolbeg Pharma PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Poolbeg Pharma PLC fundamental analysis

No fundamental analysis for Poolbeg Pharma PLC yet.

Poolbeg Pharma PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Poolbeg Pharma PLC

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza …

Full company profile